|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 45/06 | (2013.01) |
| A61K 38/17 | (2006.01) | ||
| C07K 14/735 | (2006.01) | ||
| C07K 14/71 | (2013.01) | ||
| C07K 14/71 | (2006.01) | ||
| A61K 31/519 | (2013.01) | ||
| C07K 19/00 | (2006.01) | ||
| C07K2319/30 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61P 1/00 | (2018.01) | ||
| A61P 19/00 | (2006.01) | ||
| A61P 1/08 | (2018.01) | ||
| A61P 1/14 | (2018.01) | ||
| A61P 1/16 | (2018.01) | ||
| A61P 11/00 | (2018.01) | ||
| A61P 17/00 | (2018.01) | ||
| A61P 19/00 | (2018.01) | ||
| A61P 19/02 | (2018.01) | ||
| A61P 21/00 | (2018.01) | ||
| A61P 25/02 | (2018.01) | ||
| A61P 27/02 | (2018.01) | ||
| A61P 29/00 | (2018.01) | ||
| A61P 29/02 | (2018.01) | ||
| A61P 3/02 | (2018.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61P 43/00 | (2018.01) | ||
| A61P 7/00 | (2018.01) | ||
| A61P 7/04 | (2018.01) | ||
| A61P 7/06 | (2018.01) | ||
| A61P 9/00 | (2018.01) | ||
| A61P 9/12 | (2018.01) |
| (11) | Number of the document | 3331550 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16833893.7 |
| Date of filing the European patent application | 2016-08-04 | |
| (97) | Date of publication of the European application | 2018-06-13 |
| (45) | Date of publication and mention of the grant of the patent | 2022-11-02 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2016/045631 |
| Date | 2016-08-04 |
| (87) | Number | WO 2017/024171 |
| Date | 2017-02-09 |
| (30) | Number | Date | Country code |
| 201562201058 P | 2015-08-04 | US | |
| 201562263603 P | 2015-12-04 | US |
| (72) |
KUMAR, Ravindra , US
SURAGANI, Naga, Venkata Sai Rajasekhar , US
|
| (73) |
Acceleron Pharma Inc. ,
128 Sidney Street, Cambridge, MA 02139,
US
|
| (54) | COMPOSITION FOR TREATING MYELOPROLIFERATIVE DISORDERS |
| COMPOSITION FOR TREATING MYELOPROLIFERATIVE DISORDERS |